Leukaemia Clinical Trials

7 recruiting

Leukaemia Trials at a Glance

68 actively recruiting trials for leukaemia are listed on ClinicalTrialsFinder across 6 cities in 48 countries. The largest study group is Phase 2 with 34 trials, with the heaviest enrollment activity in Paris, Copenhagen, and London. Lead sponsors running leukaemia studies include AstraZeneca, Australasian Leukaemia and Lymphoma Group (ALLG), and Princess Maxima Center for Pediatric Oncology.

Browse leukaemia trials by phase

Treatments under study

About Leukaemia Clinical Trials

Looking for clinical trials for Leukaemia? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Leukaemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Leukaemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 68 trials

Recruiting
Phase 1Phase 2

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2Phase 3

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 1Phase 2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic LeukaemiaAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 4

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Heart FailureChronic Lymphocytic Leukaemia
AstraZeneca60 enrolled23 locationsNCT06651970
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting

Leukemia Adapted Protocol

Acute Myeloid Leukaemia
Baylor College of Medicine30 enrolled1 locationNCT06928909
Recruiting
Phase 1Phase 2

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Relapsed or Resistant Acute Leukaemias
Lin BioScience, Inc90 enrolled17 locationsNCT05756322
Recruiting
Phase 1Phase 2

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Acute Myeloblastic LeukaemiaLeukemia, T-Cell
Gyala Therapeutics33 enrolled2 locationsNCT07471789
Recruiting
Phase 1

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital27 enrolled4 locationsNCT06326021
Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled5 locationsNCT07154823
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+4 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Phase 1Phase 2

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

SarcomaCancerLeukaemia+2 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Not Applicable

The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment

Acute Lymphoblastic LeukemiaAcute Myeloblastic LeukaemiaChildhood Acute Leukemia
Ege University60 enrolled1 locationNCT07203742
Recruiting
Phase 1Phase 2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Non-Hodgkin LymphomaMultiple MyelomaChronic Lymphocytic Leukaemia
Bristol-Myers Squibb50 enrolled8 locationsNCT06357754
Recruiting
Not Applicable

Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy

Acute Lymphoblastic Leukaemias (ALL)Long Term Follow-Up
University of Erlangen-Nürnberg Medical School30 enrolled1 locationNCT07313878
Recruiting
Not Applicable

xDRIVE for Florida-based Cancer Patients

CancerLeukaemiaLymphoma+5 more
First Ascent Biomedical Inc.210 enrolled2 locationsNCT07167381
Recruiting
Not Applicable

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

LeukaemiaLymphomaMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Zhongnan Hospital196 enrolled1 locationNCT07305337
Recruiting
Phase 2

Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPN
Institute of Hematology & Blood Diseases Hospital, China47 enrolled1 locationNCT07165769